Halyard Health, Inc. (NYSE:HYH) was upgraded by investment analysts at TheStreet from a “c” rating to a “b” rating in a research report issued to clients and investors on Thursday.

Several other research firms have also weighed in on HYH. Stifel Nicolaus lifted their price objective on Halyard Health from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, February 28th. Stephens lowered Halyard Health from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 28th. Finally, Zacks Investment Research lowered Halyard Health from a “hold” rating to a “sell” rating in a research report on Thursday, March 2nd. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $40.50.

Shares of Halyard Health (NYSE HYH) traded up 2.19% during midday trading on Thursday, hitting $39.73. The company’s stock had a trading volume of 852,649 shares. Halyard Health has a 1-year low of $30.88 and a 1-year high of $41.84. The company has a market cap of $1.86 billion, a P/E ratio of 48.39 and a beta of 1.79. The company has a 50-day moving average price of $37.16 and a 200 day moving average price of $38.29.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.05. Halyard Health had a return on equity of 8.16% and a net margin of 2.40%. The firm had revenue of $395.60 million during the quarter, compared to analyst estimates of $391.56 million. During the same period last year, the company posted $0.53 EPS. The business’s quarterly revenue was up 2.8% on a year-over-year basis. On average, equities research analysts predict that Halyard Health will post $1.85 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/06/25/halyard-health-inc-hyh-stock-rating-upgraded-by-thestreet.html.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock worth $226,229,000 after buying an additional 5,847,442 shares during the last quarter. Norges Bank purchased a new stake in shares of Halyard Health during the fourth quarter worth approximately $38,025,000. Cambiar Investors LLC purchased a new stake in shares of Halyard Health during the fourth quarter worth approximately $25,026,000. Copper Rock Capital Partners LLC purchased a new stake in shares of Halyard Health during the first quarter worth approximately $26,763,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Halyard Health by 704.7% in the third quarter. JPMorgan Chase & Co. now owns 608,265 shares of the medical instruments supplier’s stock worth $21,082,000 after buying an additional 532,677 shares during the last quarter. 91.87% of the stock is owned by institutional investors and hedge funds.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.